Drug Trial Radar · NCT00317707
Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk
Last checked: Nov 20, 2026Latest source record: Jan 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,513
Actual
Start
Feb 2004
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 25, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the everyday practice cardiovascular prevention in people at high risk is still unsatisfactory and treatments with documented efficacy are generally under-used. Polyunsaturated fatty acids of marine origin (n-3 PUFA) are the latest more promising strategy to improve prognosis in these patients. The Risk and Prevention study combines an epidemiological and an experimental approach in order to: 1. Verify the possibility to optimise cardiovascular prevention in subjects at high risk by planning the intervention with patients and setting individual goals (outcome study) 2. Evaluate the efficacy of a long term n-3 PUFA treatment in reducing the incidence of cardiovascular events, through a controlled, randomised, double blind clinical trial.
Conditions
- Cardiovascular Diseases
Interventions
N-3 Polyunsaturated Fatty AcidsDrug
Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
Placebo: Olive oilDrug
Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
Primary outcomes
What the sponsor says the trial is designed to measure.
- cardiovascular deaths and hospitalization for cardiovascular causesTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mario Negri Institute for Pharmacological Research
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.